Remove 2007 Remove FDA Remove Food and Drug Administration
article thumbnail

Innovating allergy drug delivery with a needle-free alternative

European Pharmaceutical Review

This decision was granted a couple of weeks following approval by the US and Drug Administration (FDA). Approximately 40 million people in the US experience Type I allergic reactions due to food, venom or insect stings, 4 and the numbers are similar in Europe. 2007; 2(1):5-11. Hand (N Y). Lowenthal R.

article thumbnail

The lingering menace of diethylene glycol / ethylene glycol adulteration

European Pharmaceutical Review

The following year, the US Congress passed the 1938 Federal Food, Drug and Cosmetic (FD&C) Act, which mandated safety assessments prior to the release of any new drug. There is now global awareness of this issue and FDA issued a guidance note on the problem in 2007. Pharmacopoeia guidance on DEG and EG.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Interview: Dr Alan S Louie – US Food and Drug Administration Delays

Pharmaceutical Technology

Nicola Boyes: The FDA has come under criticism recently for extreme delays in approving new drugs for the market, is the criticism valid and if so how are the delays impacting on the US pharmaceutical industry at present? This higher threshold, although not explicit, would also be expected to slow drug approvals.

article thumbnail

First continuous mRNA manufacturing platform to be developed

European Pharmaceutical Review

The $82 million project is funded by the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research. This $85 million programme ran between 2007 and 2019. Continuous manufacturing should also improve the quality of mRNA production through automation and in-line analytics, Braatz noted.

article thumbnail

Developing a holistic approach to cardio, metabolic and renal disease

European Pharmaceutical Review

This theory has been supported by the clinical results of drugs such as empagliflozin, the SGLT2 inhibitor, across several of these conditions. The drug advanced through to Phase II trials in adults living with obesity and also those with NASH in 2021. This programme has received FDA Fast Track designation.

article thumbnail

GERTEIS® PACTOR® SERIES In-Line Ribbon-Strength Measurement System

Pharmaceutical Technology

The importance of ribbon density has previously been emphasized by Helen Winkle [1] from the US Food and Drug Administration (FDA) and it becomes clear then that maintaining the ribbon density by setting the correct force and gap is crucial for the final granulates.

article thumbnail

THEPM360TRAILBLAZER AWARD WINNER – Lifetime Achievement Award – Adam Schechter, CEO and Chairman, Labcorp

PM360

Prior to becoming President of Global Human Health, he served as President of Merck’s global pharmaceutical business from 2007 to 2010. Food and Drug Administration (FDA) approval. Adam strives for every person he sees to know him, trust him, and receive the same respect as himself.

Ethics 59